Spitalul Clinic Filantropia

The medical center is at the forefront of breast cancer research, focusing on innovative treatments for cases that cannot be surgically removed. The center is conducting a pivotal clinical trial comparing the efficacy of MK-2870 with or without pembrolizumab against traditional chemotherapy.

• Hormone receptor positive breast cancer
• Progression-free survival (PFS) assessment
• RECIST 1.1 criteria evaluation

This research aims to enhance therapeutic options and improve outcomes for patients with advanced breast cancer.

Specializing in the treatment of vaginitis, the center is conducting a comprehensive study to establish the non-inferiority of a new combination therapy of metronidazole, Neomycin Sulfate, and nystatin compared to existing treatments. This research is crucial for addressing both specific and non-specific vaginitis.

• Bacterial vaginosis (BV)
• Vulvovaginal candidiasis (VVC)
• Clinical and microbiologic/mycological cure

The study's findings are expected to provide safer and more effective treatment options for female patients.

The center is advancing the treatment of triple-negative breast cancer through a study comparing sacituzumab govitecan-hziy with the treatment of physician's choice. This research is particularly focused on patients with previously untreated locally advanced inoperable or metastatic conditions.

• PD-L1-negative metastatic triple-negative breast cancer
• PD-L1-positive metastatic triple-negative breast cancer
• Anti-PD-(L)1 agent pre-treated patients

The study aims to improve progression-free survival rates and offer new hope for patients with challenging cancer profiles.